Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVTXNASDAQ:BYSINASDAQ:ELDNNASDAQ:PPBT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$13.00+6.5%$8.64$3.95▼$1,130.40$13.39M1.13554,687 shs73,223 shsBYSIBeyondSpring$2.29+8.5%$2.37$0.65▼$4.00$89.13M0.14188,369 shs112,151 shsELDNEledon Pharmaceuticals$2.16+6.9%$1.79$1.07▼$2.95$53.59M0.8788,598 shs189,922 shsPPBTPurple Biotech$0.49+8.9%$0.68$0.30▼$2.10$12.37M0.94109,869 shs82,150 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+4.99%-19.88%+150.20%+168.35%-98.25%BYSIBeyondSpring+10.47%+19.89%-32.37%+134.97%+95.37%ELDNEledon Pharmaceuticals+8.60%+23.17%+0.50%+18.82%-23.77%PPBTPurple Biotech-0.35%-19.99%-32.44%-24.71%-76.75%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTXAvalo Therapeutics0.2763 of 5 stars0.02.00.00.03.71.70.0BYSIBeyondSpring0.0033 of 5 stars0.00.00.00.00.02.50.0ELDNEledon Pharmaceuticals2.3137 of 5 stars3.53.00.00.01.11.71.3PPBTPurple Biotech1.6271 of 5 stars3.54.00.00.01.10.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics2.50Moderate BuyN/AN/ABYSIBeyondSpringN/AN/A$1.25-45.41% DownsideELDNEledon Pharmaceuticals3.00Buy$10.67393.83% UpsidePPBTPurple Biotech3.00Buy$9.001,736.73% UpsideCurrent Analyst RatingsLatest BYSI, AVTX, ELDN, and PPBT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024AVTXAvalo TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform3/22/2024ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.003/5/2024PPBTPurple BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.002/27/2024PPBTPurple BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$1.92M6.97N/AN/A$9.11 per share1.43BYSIBeyondSpring$1.35M66.02N/AN/A($0.36) per share-6.36ELDNEledon PharmaceuticalsN/AN/AN/AN/A$3.45 per shareN/APPBTPurple BiotechN/AN/AN/AN/A$1.36 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$31.54M-$616.67N/AN/AN/A-1,639.50%-1,439.87%-113.95%5/2/2024 (Estimated)BYSIBeyondSpring-$33.28MN/A0.00∞N/AN/AN/AN/AN/AELDNEledon Pharmaceuticals-$40.33M-$1.79N/AN/AN/AN/A-46.15%-43.10%5/9/2024 (Estimated)PPBTPurple Biotech-$19.88M-$0.92N/AN/AN/AN/A-57.40%-49.02%5/21/2024 (Estimated)Latest BYSI, AVTX, ELDN, and PPBT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ELDNEledon Pharmaceuticals-$0.38-$0.29+$0.09-$0.29N/AN/A3/5/2024Q4 2023PPBTPurple Biotech-$0.17-$0.32-$0.15-$0.45N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A1.821.82BYSIBeyondSpringN/AN/AN/AELDNEledon PharmaceuticalsN/A14.4114.41PPBTPurple BiotechN/A2.202.20OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%BYSIBeyondSpring40.29%ELDNEledon Pharmaceuticals56.77%PPBTPurple Biotech9.64%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics0.20%BYSIBeyondSpring29.31%ELDNEledon Pharmaceuticals19.40%PPBTPurple Biotech2.98%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics191.03 million1.03 millionNot OptionableBYSIBeyondSpring7338.92 million27.52 millionOptionableELDNEledon Pharmaceuticals1724.81 million20.00 millionOptionablePPBTPurple Biotech2025.24 million24.49 millionOptionableBYSI, AVTX, ELDN, and PPBT HeadlinesSourceHeadlinePurple Biotech Ltd (PPBT)investing.com - April 17 at 11:15 PMPurple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024finance.yahoo.com - March 28 at 11:13 AMPurple Biotech Ltd.: Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technologyfinanznachrichten.de - March 14 at 12:40 PMPurple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technologyglobenewswire.com - March 14 at 7:30 AMHere's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisherzacks.com - March 13 at 10:56 AMPPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023investorplace.com - March 5 at 11:52 PMPurple Biotech Ltd.: Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinanznachrichten.de - March 5 at 1:22 PMPurple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Resultsglobenewswire.com - March 5 at 7:55 AMPurple Biotech ADR (PPBT) Earnings Dates & Reportsinvesting.com - March 3 at 6:09 PMBuy Rating Justified by Promising Phase 1 Results of Purple Biotech’s NT219 in SCCHN Treatmentmarkets.businessinsider.com - February 27 at 10:57 PMPurple Biotech Ltd ADRmorningstar.com - February 27 at 5:56 PMPurple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024globenewswire.com - February 27 at 7:00 AMPurple Biotech Ltd. ADRwsj.com - February 22 at 2:20 PMPurple Biotech Ltd ADR PPBTmorningstar.com - February 15 at 12:30 AMPurple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trialfinance.yahoo.com - February 13 at 8:34 AMAnalysts Offer Insights on Healthcare Companies: Purple Biotech (PPBT) and Sanofi (OtherSNYNF)markets.businessinsider.com - February 1 at 5:47 PMPurple Biotech stock climbs 9% on Phase 2 study updatemsn.com - February 1 at 12:47 PMPurple Biotech Reaches Recommended Phase 2 Dose for NT219finance.yahoo.com - February 1 at 7:47 AMPurple Biotech Appoints Dr. Yael Margolin to its Board of Directorsfinance.yahoo.com - December 20 at 9:18 AMPurple Biotech Ltd.: Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trialfinanznachrichten.de - December 14 at 10:30 AMPurple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trialfinance.yahoo.com - December 14 at 10:30 AMEncouraging Early Data For Biotech's Cancer Therapiesinvestorideas.com - November 22 at 12:58 PMPromising Clinical Trial Results and Accelerated Enrollment Boost Purple Biotech’s Buy Ratingmarkets.businessinsider.com - November 22 at 7:58 AMPurple Biotech Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 21 at 10:25 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAvalo TherapeuticsNASDAQ:AVTXAvalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.BeyondSpringNASDAQ:BYSIBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.Eledon PharmaceuticalsNASDAQ:ELDNEledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Purple BiotechNASDAQ:PPBTPurple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.